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A method for reversibly, or irreversibly, altering the perme-
ability of cells, tissues or other biological barriers, to mol-
ecules to be transported into or through these materials, 
through the application of acoustic energy, is enhanced by 
applying the ultrasound in combination with devices for 
monitoring and/or implementing feedback controls. The 
acoustic energy is applied directly or indirectly to the cells 
or tissue whose permeability is to be altered, at a frequency 
and intensity appropriate to alter the permeability to achieve 
the desired effect, such as the transport of endogenous or 
exogenous molecules and/or fluid, for drug delivery, mea-
surement of analyte, removal of fluid, alteration of cell or 
tissue viability or alteration of structure of materials such as 
kidney or gall bladder stones. In the preferred embodiment, 
the method includes measuring the strength of the acoustic 
field applied to the cell or tissue at the applied frequency or 
other frequencies, and using the acoustic measurement to 
modify continued or subsequent application of acoustic 
energy to the cell or tissue. In another preferred embodi-
ment, the method further includes simultaneously, previ-
ously, or subsequently exposing the cell or tissue to the 
chemical or biological agent to be transported into or across 
the cell or tissue. In another preferred application, the 
method includes removing biological fluid or molecules 
from the cells or tissue simultaneously, previously or sub-
sequently to the application of acoustic energy and, option-
ally, assaying the biological fluid or molecules. 
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METHOD OF APPLYING ACOUSTIC 
ENERGY EFFECTIVE TO ALTER 
TRANSPORT OR CELL VIABILITY 
2 
different conditions (that is, a spectrum oflower frequencies 
and high intensity), routine lithotripsy procedures use 
focused acoustic energy to noninvasively shatter kidney 
stones so the fragments can be excreted by the body without 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
Priority is claimed to U.S. Provisional applications Ser. 
No. 60/071,240, filed Jan. 12, 1998, and Ser. No. 60/085, 
304, filed May 13, 1998. 
5 surgery (Coleman and Saunders, Ultrasonics 31: 75-89 
(1993)). Kidney stone destruction by lithotripsy is believed 
to be mediated by cavitation. Tachibana, et al., Cancer Lett. 
78(1-3): 177-181 (1994); Cancer Lett. 72(3): 195-199 
(1993) have reported on the use of topically applied ultra-
BACKGROUND OF THE INVENTION 
10 sound in combination with a photosensitizer to kill tumor 
cells and on the combination of topically applied ultrasound 
in combination with gas containing microspheres to enhance 
lysis of thrombi, in Circulation 92(5): 1148-1150 (1995) and 
The present invention is in the field of controlled appli-
cation of acoustic energy to tissues and cells, and more 15 
particularly to assessment and control of acoustic energy as 
a means of enhancing the permeability of cell and tissue for 
administration of chemical or biological agents. 
Ultrasound-mediated administration of drugs, genes, and 
other therapeutic compounds into and across cells and 20 
tissues has shown significant potential in target drug deliv-
ery. For example, studies have shown that appropriately 
applied ultrasound can reversibly permeabilize viable cells 
so that exogenous material can enter those cells without 
killing them. Ultrasound-enhanced delivery to cells has been 25 
demonstrated in vitro by uptake of extracellular fluid (Wil-
liams, J. Cell Sci. 12: 87 5-85 (1973) ); drugs (Saad and Hahn, 
Ultrasound Med. Biol. 18: 715-23 (1992)); and DNA into 
both cells (Fechheimer, et al., Proc. Natl. Acad. Sci. USA 84: 
8463-67 (1987); Kim, et al., Human Gene Ther. 7: 1339-46 30 
(1996); Bao, et al., Ultrasound Med. Biol. 23: 953-59 
(1997); Wyber, et al., Pharm. Res. 14: 750-56 (1997)) and 
plant tissues (Zhang, et al., Bio/Technology 2: 996-97 
(1991)). 
U.S. Pat. No. 5,315,998 to Tachibana, et al. 
Acoustic cavitation involves the creation and oscillation 
of gas bubbles in a liquid (Leighton, The Acoustic Bubble 
(Academic Press, London (1994)). During the low-pressure 
portion of an ultrasound wave, dissolved gas and vaporized 
liquid can form gas bubbles. These bubbles then shrink and 
grow in size, oscillating in response to the subsequent 
high-and low-pressure portions of the ultrasound wave, a 
process referred to as stable cavitation. Transient cavitation 
occurs at greater acoustic pressures, where bubbles violently 
implode after a few cycles. This implosion can have a 
number of effects, including transiently raising the local 
temperature by hundreds of degrees Celsius and the local 
pressure by hundreds of atmospheres, emitting light by a 
poorly-understood phenomenon called sonoluminescence, 
creating short-lived free radicals, and launching a high-
velocity liquid microjet. Cavitation also is believed to be 
responsible for ultrasonic permeabilization of cells and 
tissues of interest for pharmaceutical applications (Wyber, et 
al., Pharm. Res. 14: 750-56 (1997); Mitragotri, et al., 
Pharm. Res. 13: 411-20 (1996); Barnett, et al., Ultrasound 
35 Med. Biol. 20: 205-18 (1994)). Nonetheless, the effects of 
ultrasound parameters on cavitation and cell membrane 
permeabilization are not sufficiently understood for devel-
opment and optimization of acoustic techniques in, for 
Similarly, acoustic effects of lithotripters have been 
shown to permeabilize cell membranes. (Holmes, et al., J. 
Ural. 147: 733-37 (1992); Gambihler, et al., J. Membr. Biol. 
141: 267-75 (1994)). Ultrasound also has been shown to 
increase transport of small drugs and proteins across skin, 
which is of interest for topical and systemic transdermal 40 
drug delivery (Kost and Langer, "Ultrasound-mediated 
transdermal drug delivery" in Topical Drug Bioavailability, 
Bioequivalence, and Penetration (Shah & Maibach (eds.)) 
pp. 91-104 (Plenum Press, New York 1993); Mitragotri, et 
al., Pharm. Res. 13: 411-20 (1996); (Mitragotri, et al., 45 
Science 269: 850-53 (1995); Prausnitz, "Transdermal deliv-
ery of proteins: recent advances by modification of skin's 
barrier properties" in Therapeutic Protein and Peptide For-
mulation and Delivery (Shahrokh, et al., eds.) pp. 124-53 
(American Chemical Society, Washington, D.C. 1997)). 
example, controlled drug delivery. 
It is therefore an object of this invention to provide 
quantitative assessment and control of acoustic tissue 
effects. 
It is another object of this invention to provide means for 
enhancing the controlled transportation of molecules into or 
across cell or tissue barriers. 
It is still another object of this invention to provide means 
for reversibly or irreversibly altering cell or tissue perme-
ability, thereby regulating transport or cell or tissue proper-
50 ties such as viability or structure. 
Ultrasound has been a well established diagnostic and 
therapeutic tool in medicine for decades (Stewart and Strat-
meyer, eds., An Overview of Ultrasound. Theory, Measure-
ment, Medical Applications, and Biological Effects (FDA 
82-8190) (U.S. Department of Health and Human Services, 55 
Rockville, Md. 1983); Suslick, ed., Ultrasound: Its Chemi-
cal, Physical, and Biological Effects (VCH, Deerfield 
Beach, Fla. 1988)). Ultrasonic imaging is widely used at 
high frequency and low intensity conditions, which are 
believed to cause no or minimal effects on cells (Barnett, et 60 
al., Ultrasound Med. Biol. 20: 205-18 (1994)). Ultrasound 
also is used therapeutically at somewhat greater intensities 
to heat tissues for physical therapy and other hyperthermia 
treatments (Exposure Criteria for Medical Diagnostic Ultra-
sound: I. Criteria Based on Thermal Mechanisms (NCRP 65 
Report No. 113), National Council on Radiation Protection 
and Measurements (Bethesda, Md. 1992)). Under a very 
SUMMARY OF THE INVENTION 
A method for reversibly, or irreversibly, altering the 
permeability of cells, tissues or other biological barriers, to 
molecules to be transported into or through these materials, 
through the application of acoustic energy, is enhanced by 
applying the ultrasound in combination with means for 
monitoring and/or implementing feedback controls. The 
acoustic energy is applied directly or indirectly to the cells 
or tissue whose permeability is to be altered, at a frequency 
and intensity appropriate to alter the permeability (which 
includes diffusivity) to achieve the desired effect, such as the 
transport of endogenous or exogenous molecules and/or 
fluid, for drug delivery, measurement of analyte, removal of 
fluid, alteration of cell or tissue viability or alteration of 
structure of materials such as kidney or gall bladder stones. 
US 7,273,458 B2 
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In the preferred embodiment, the method includes mea-
suring the strength of the acoustic field applied to the cell or 
tissue at the applied frequency or other frequencies, and 
using the acoustic measurement to modify continued or 
subsequent application of acoustic energy to the cell or 
tissue. In another preferred embodiment, the method further 
includes simultaneously, previously, or subsequently expos-
ing the cell or tissue to the chemical or biological agent to 
be transported into or across the cell or tissue. In another 
preferred application, the method includes removing bio- 10 
logical fluid or molecules from the cells or tissue simulta-
neously, previously or subsequently to the application of 
acoustic energy and, optionally, assaying the biological fluid 
or molecules. 
In a preferred embodiment, the acoustic energy is applied 15 
at a frequency between about 1 kHz and 20 MHz, and at a 
peak positive pressure up to 100 atmospheres. The acoustic 
energy can be applied directly to the tissue or cells where the 
effect is desired. Alternatively, the acoustic energy can be 
applied at a site at a distance from the transducer, under 20 
conditions designed to result in a desired effect at the distant 
site. Ultrasound can be applied using non-invasive means 
(for example, by transdermal application), minimally inva-
sive means (for example, using a catheter), or during surgery 
or other invasive procedures. the acoustic energy can be 25 
applied alone, or in combination with therapeutic or diag-
nostic agents. 
The method can be used in a variety of applications, 
including drug delivery, including gene therapy, administra-
30 
ti on of vaccines, and administration of targeted therapeutic 
or diagnostic agents. detection and/or quantitation of ana-
lyte, and destruction of tissues such as cancers, fatty tissue 
or materials such as kidney or gall bladder stones. 
4 
FIG. 8 is a graph showing average uptake of calcein 
molecules per cell as a function of time at which calcein was 
added to the cell suspension after exposure. 
DETAILED DESCRIPTION OF THE 
DISCLOSURE 
Acoustic energy can be used to cause chemical or bio-
logical agents to be transported into and/or across biological 
barriers, for example, in cells or tissue. Characterizing the 
dependence of cell membrane permeabilization on acoustic 
energy conditions is, however, essential to rationally design-
ing acoustic energy protocols for pharmaceutical and other 
applications. Accordingly, methods are provided herein to 
use the quantitative dependence of cell membrane perme-
abilization on various acoustic parameters to enhance the 
transport of chemical or biological agents to be transported 
into and/or across biological barriers in cells or tissue, for 
example, to enhance delivery of drugs to cells in a specific 
tissue or to increase uptake of compounds which cross cell 
membranes poorly. 
I. Acoustic Energy 
As used herein, the term "acoustic energy" means any 
form of pressure wave, whether audible or inaudible. The 
frequency of the acoustic energy can be a single frequency 
or a combination of frequencies. The range of useful fre-
quencies preferably is between about 1 Hz and 100 MHz, 
and more preferably is between about 1 kHz and 10 MHz 
and most preferably between 15 kHz and 2 MHz. The 
waveform of the acoustic energy can be of any shape, 
including a sinewave or a combination of sinewaves. The 
pressure of the acoustic energy can be up to a few hundred 
atmospheres, and preferably is applied at a peak positive 
pressure of up to 100 atmospheres. The optimal pressure is 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. la and lb are graphs of incident ultrasonic pressure 
(la) and subharmonic pressure (lb) versus percent mem-
brane permeabilization of a suspension of bovine red blood 
cells exposed to continuous ultrasound for 10 sec. at 24 kHz. 
35 a function of acoustic frequency and other parameters 
described below. The acoustic energy can be applied con-
tinuously or intermittently. 
FIG. 2 is a graph of ultrasound frequency versus pressure, 
which illustrates a representative acoustic spectrum mea-
sured during an ultrasound exposure at f=24 kHz, which 
caused extensive cavitation. 
FIG. 3 is a graph of ultrasound exposure time versus 
percent membrane permeabilization for red blood cells 
exposed to continuous ultrasound at 24 kHz for different 
amounts of time at incident pressures of 0.89 atm. ( + ), 2.7 
atm. (•), and 8.9 atm. (•). 
FIG. 4 is a graph of length of time of an ultrasound pulse 
versus percent membrane permeabilization of cells for 
pulses applied at a duty cycle of 10% at incident pressures 
of 0.89 atm. ( + ),2.7 atm. (•), and 8.9 atm. (•). 
FIG. 5 is a graph of ultrasound duty cycle (%) versus 
percent membrane permeabilization at an incident pressure 
of 2.7 atm., for a total "on" time of 10 sec. at a pulse length 
of 0.1 sec.(+) or 1 sec. (•). 
Acoustic energy can be used to enhance transport by a 
number of different mechanisms, which broadly fall into two 
40 classes. In the first class, acoustic energy directly or indi-
rectly (e.g., via cavitation) provides a driving force for 
transport. In the second class, acoustic energy increases the 
permeability of the biological barrier, either reversibly, 
partially reversibly, or irreversibly. These two mechanisms 
45 can be used independently or in combination. In the pre-
ferred embodiment, both mechanisms are used simulta-
neously. 
In the first class, where acoustic energy directly or indi-
rectly provides a driving force for transport, both cavita-
50 tional and non-cavitational mechanisms can be involved. 
Under appropriate low frequency, high pressure conditions, 
acoustic energy can cause cavitation, which is the creation of 
gas cavities, or bubbles, which oscillate stably in the acous-
tic field and/or collapse, as can be seen during transient or 
55 inertial cavitation. The appropriate conditions will depend 
on the temperature, gas content, acoustic conditions, viscos-
ity and the other properties of the system and acoustic field. 
Cavitational and non-cavitational acoustic energy also can 
FIG. 6 is a graph of the acoustic parameter i:-Pf72 versus 60 
percent membrane permeabilization, using the data from 
FIGS. 1-5. 
provide convective or hydrodynamic driving forces for 
transport, including acoustic streaming, microstreaming, 
and local, high-velocity jets caused by transient cavitation. 
Also, chemical and other changes caused by acoustic energy 
can alter the local environment, thereby changing local 
chemical potentials, which can alter the chemical potential 
FIG. 7 is a graph showing average uptake of calcein 
molecules per exposed cell ( o) and fraction of viable cells 
(•) relative to unexposed control, each as a function of peak 
incident pressure for 20 pulses at 0.1 sec. and 10% duty 
cycle. 
65 driving force for net transport by diffusion. 
In the second class, where acoustic energy increases the 
permeability of the biological barrier, either reversibly, 
US 7,273,458 B2 
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partially reversibly, or irreversibly, both cavitational and 
non-cavitational mechanisms can be involved. For example, 
increased permeability can be achieved by heating, thereby 
increasing diffusivity of the molecules. Increased permeabil-
6 
II. Chemical or Biological Agents 
ity can also be achieved by altering physical structures 
within biological barriers, such as re-organizing the struc-
ture of lipid bilayers, intercellular junctions, and extracel-
lular matrix. These physical effects can be caused by one or 
more factors, including bulk heating, cavitation, acoustic 
streaming, microstreaming, high-velocity jets, mechanical 10 
interactions, local heating by cavitation, local pressure 
increases by cavitation, and chemical effects due to creation 
The methods described herein can be used to enhance 
transport of essentially any endogenous or exogenous 
chemical or biological agent for therapeutic, diagnostic, or 
prophylactic purposes into or across biological barriers. 
Useful agents include peptides, proteins, sugars, polysac-
charides, nucleotides, polynucleotide molecules, and other 
synthetic organic or inorganic compounds. Representative 
proteins and peptides include hormones such as insulin, 
growth factors, and vaccines. Representative polynucleic 
acid molecules include antisense, aptamers, ribozymes, and 
genes, plasmids, and viral vectors. Representative synthetic 
organic or inorganic drugs include anti-inflammatories, anti-
virals, antifungals, antibiotics and local anesthetics. As used 
of free radicals, or stimulation of other chemical reactions. 
Preselected Conditions 
Acoustic enhancement can be used to alter transport 
(typically by altering permeability to the molecules to be 
transported to the material through which they are to pass) 
or structural integrity of biological materials. The param-
eters can be selected prior to application, based on previous 
studies or empirical results. In a preferred method, however, 
feedback is obtained so that the acoustic enhancement is 
modified after the initial application as needed to optimize 
results as treatment progresses. 
Acoustic Measurement Feedback 
15 herein, the agents can be molecules or aggregates or other 
multi-molecular structures, including for example, virus 
particles or cells, liposomes or other lipid vesicles or emul-
sions, or particles including nano or microspheres or cap-
sules. For direct application, the drug will typically be 
20 administered in an appropriate pharmaceutically acceptable 
carrier having an acoustic impedance similar to water, such 
as an aqueous gel, ointment, lotion, or suspension. Alterna-
tively, a transdermal patch can be used as a carrier. 
Feedback can involve measurement of one or more vari- 25 
A variety of analytes are routinely measured in the body 
fluids such as blood, interstitial fluid, lymph, intracellular 
fluid or cerebral spinal fluid. Examples of typical analytes 
that can be measured include blood sugar (glucose), cho-
lesterol, bilirubin, creatinine, vitamin K or other clotting 
factors, uric acid, carcinoembryonic antigen or other tumor 
30 antigens, and various reproductive hormones such as those 
associated with ovulation or pregnancy. Other analytes that 
can be measured include alcohol and drugs. 
III. Applications 
ables. Variables include subharmonic pressure, acoustic 
parameters, temperature, amount or rate of transport of 
molecules, extent of cavitation, and degree of permeabili-
zation. In one embodiment, the acoustic energy or pressure 
is measured at one or more frequencies other than the 
frequency or frequencies at which the acoustic energy is 
applied. For example, the acoustic energy or pressure is 
measured at a frequency or frequencies corresponding to 
integer multiples of one-half or one-fourth of the frequency 
applied. 35 
The methods described herein can be used to enhance 
transport of agents into or across a variety of biological 
barriers. Representative barriers include mammalian and 
non-manimalian tissues, including skin, tumor, muscle, 
lung, brain, heart, blood vessel, bone, cartilage, and internal 
As described in Example 1 below, membrane permeabi-
lization is mediated by cavitation, so that subharmonic 
pressure can be used as a noninvasive way to determine the 
degree of permeabilization resulting from exposure to 
acoustic energy. In addition, permeabilization caused by 
ultrasound should be well predicted by the acoustic param-
eter i:·Pf72 , which characterizes the total cavitational expo-
sure by accounting for both the strength of the f/2 cavitation 
signal and the time over which it acts. 
In a preferred embodiment, the method of enhancing 
transport of chemical or biological agents across or into a 
biological barrier includes the following steps: 
(a) applying acoustic energy to the biological barrier, for 
example, the cells or tissue, at one or more frequencies; 
(b) measuring the strength of the acoustic field applied to 
the cells or tissue at the applied frequency or other frequen-
cies; and 
40 organs. The tissue or cell can be a part of a living organism, 
obtained from a living organism, or intended to become part 
of a living organism, for example, for use in tissue regen-
eration or tissue engineering, in the form of tissue or 
dissociated cells. Other representative biological barriers 
45 include externally accessible barriers, such as skin, the eye (cornea, conjunctiva, sclera), and the mucosa of the nose, 
mouth, rectum and vagina, as well as internal barriers, such 
as the gastrointestinal tract and pulmonary mucosa, blood 
and lymphatic vessel walls (including the blood-brain bar-
50 rier), internal organs, tumors, and bones. The barrier can be 
in the form of intercellular junctions, extracellular matrices, 
or cell membranes for introduction of material into or out of 
the interior of a cell or cells. In one preferred embodiment, 
( c) using the acoustic measurement obtained in step (b) to 
modify continued or subsequent application of acoustic 55 
energy to the cells or tissue. 
the biological barrier is human skin. 
As used herein, the phrase "biological barrier" encom-
passes cell membranes, tissue, tissue membranes, intracel-
lular membranes, and biological materials such as kidney 
stones. It is understood that the technology can be applied 
directly or indirectly to these materials. 
For example, in a preferred embodiment, a device applies 
ultrasound to a tissue and the f/2 signal is measured to assess 
the degree to which the tissue was permeabilized. This 
information can be used to estimate the amount of drug 60 
delivered. Measurement of the f2 signal provides a method 
for real-time feedback so that the ultrasound exposure based 
The methods of enhancing transport can be performed 
with acoustic energy parameters that are preselected and/or 
that are adjusted based on acoustic measurement feedback. 
on pre-programmed or user-selected drug delivery profiles 
can be optimized. The technology required for both gener-
ating acoustic energy and "listening" to f/2 signals is known 
in the art, relatively inexpensive when mass produced, and 
is readily miniaturizable. 
Acoustic enhancement can preceed, occur simulta-
neously, or follow treatment with other agents which may be 
65 used in combination with the ultrasound to affect transport. 
For example, chemical enhancers that increase solubility of 
the materials to be transported, permeability enhancers, or 
US 7,273,458 B2 
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even other driving forces such as mechanical or physical 
forces (vacuum, pressure, electrical forces) may be used 
with the ultrasound. 
8 
type. The transport of these compounds also can be 
enhanced by application of acoustic energy. For example, in 
gene therapy, a target tissue could be treated with acoustic 
energy to facilitate delivery of DNA into cells. 
The compositions and methods of preparation and use 
thereof described herein are further described by the fol-
lowing non-limiting examples. 
EXAMPLE 1 
Exposure of Bovine Red Blood Cells to Ultrasound 
Acoustic enhancement which is administered to enhance 
transport out of cells or tissues, for example, for measure-
ment of analyte, is administered in an amount which is 
effective, alone or in combination with other transport 
enhancers, to extract analyte for detection or quantitation. 
Acoustic enhancement which is administered to enhance 
transport of fluid out of tissue or cells is administered in an 10 
amount which is effective, alone or in combination with 
other transport enhancers, to extract fluid, for example, as 
required to reduce swelling or shrink tissue for easier 
extraction using other methods or to facilitate breakdown of 
structural integrity. 
The dependence of cell membrane permeabilization on 
ultrasound parameters was determined and the acoustic 
15 signals which correlate with observed membrane permeabi-
lization were identified. Acoustic enhancement which is administered to degrade 
structural integrity or kill cells is administered in an amount 
effective to dissociate cells or tissue or other material such 
as a kidney or gall bladder stone (usually formed of calcium 
and/or lipid materials) or to irreversibly alter the cell per- 20 
meability so that the cells become unviable. 
Acoustic enhancement which is administered to enhance 
transport is administered directly or indirectly as required to 
alter the rate or extent of transport. Enhancement may be 
measured by an increase in transport, for example, using a 25 
marker such as blood levels following transdermal delivery, 
or through an end result, for example, following introduction 
of genes into tissue, by expression of the product encoded by 
the genes. 
The transport methods described herein can be used to 30 
alter transport as part of a variety of procedures. Acoustic 
energy can be focused on the target tissue, using an invasive, 
minimally-invasive, or non-invasive method, to increase 
transport locally without significantly affecting other tissues. 
In a preferred embodiment, acoustic energy is applied non- 35 
invasively using one or more transducers to focus energy 
onto the body surface or at a site deeper in the body. In 
another preferred embodiment, a minimally-invasive 
method is used, in which, for example, one or more trans-
ducers are attached to a laproscopic device for the treatment 40 
of tissue accessible from the gastrointestinal tract in, for 
example, the treatment of colon cancer, or to a catheter for 
the treatment of tissue accessible from the vasculature in, for 
example, the treatment of atherosclerosis or restinosis. An 
invasive approach can be used to treat any tissue. For 45 
example, the acoustic energy can be applied in conjunction 
with another invasive procedure, such as surgery. 
In a preferred embodiment, transdermal delivery of a 
drug, such as insulin, is enhanced by the use of acoustic 
energy to cause compounds to be transported into and/or 50 
across the skin. In another preferred embodiment, a biologi-
cal material, such as glucose, is transported out of the body 
through/from the skin using a method facilitated by acoustic 
energy. 
Experimental Methods 
Bovine red blood cells were exposed to ultrasound at 24 
kHz over a range of controlled conditions. The degree of 
membrane permeabilization was measured by release of 
hemoglobin and was determined as a function of ultrasound 
parameters and measured acoustic signals. 
Sample Preparation 
Freshly drawn bovine blood with Alsevers anticoagulant 
(Rockland, Gilbertsville, Pa.) was stored at 4° C. for up to 
10 days. Red blood cells were collected by centrifugation 
(GS-15SR, Beckman Instruments, Palo Alto, Calif.; 400 g, 
10 min., 4° C.); washed three times with phosphate-buffered 
saline (PBS; pH 7.4; Sigma, St. Louis, Mo.); and then 
suspended in PBS at a red blood cell concentration of 10% 
by volume. The cell suspension was stored on ice and then 
gently mixed on a nutator (Innovative Medical Systems, 
Ivyland, Pa.) immediately before use in an experiment. 
The cell suspension was added to a sample tube, which 
was prepared by cutting a 15 ml polypropylene centrifuge 
tube (VWR, Suwanee, Ga.) at the 4 ml line. After the sample 
tube was filled with 4 ml of the cell suspension, a rubber 
stopper (VWR) was carefully inserted into the tube to the 3 
ml line, thereby spilling out about 1 ml of the suspension. 
This procedure was used so that the tube could be sealed 
without entrapping air bubbles. A hydrophone (Baylor 
School of Medicine, Houston, Tex.) also was inserted 
through a small hole in the center of the rubber stopper and 
positioned at the center of the sample volume. 
Exposure to Ultrasound 
The ultrasound exposure chamber consisted of a cylin-
drical piezoelectric transducer (lead zirconate titanate, 5 cm 
OD, 4.5 cm ID, 2.5 cm length; Channel Industries, Santa 
Barbara, Calif.) sandwiched between two 10 cm lengths of 
1.5 inch Schedule 40 poly(vinyl chloride) (PVC) pipe. The 
bottom of the chamber was sealed on a clear polycarbonate 
base (LEXAWM, General Electric, Mt. Vernon, Ind.). The 
In a similar preferred embodiment, a drug is delivered 
from outside the body to its interior, or a molecule from 
inside the body to the exterior, across barriers other than 
skin, such as the epithelia of the eye, nose, mouth, rectum, 
55 chamber was filled with water which was filtered/deionized 
(Type III; U.S. Filter, Roswell, Ga.) and degassed using a 
vacuum chamber (Nalgene, Rochester, N.Y.; pump: 
2107VA20A, Thomas, Sheboygan, Wis.). 
or vagina, using a method facilitated by acoustic energy. 
In another preferred embodiment, acoustic energy is used 60 
to enhance targeted drug delivery by selectively increasing 
transport of a drug into a target tissue, such as the brain or 
The sample tube was placed in the water bath within the 
ultrasound exposure chamber, positioned at the axial and 
radial center of the transducer, and exposed to low-fre-
quency (24 kHz) ultrasound at room temperature (22±2° C.). 
A function generator (DS345, Stanford Research Systems, 
Surmyvale, Calif.) was programmed to provide a sinewave 
a tumor. Some tissues, such as tumors, are particularly 
resistant to transport. Accordingly, acoustic energy can sig-
nificantly enhance delivery of drug to those tissues. 
Other compounds, particularly larger macromolecules, 
are especially difficult to drive into cells or tissue of any 
65 of selected voltage, duty cycle, burst length, and total 
exposure time. The output was fed to an amplifier (Macro-
tech 2400, Crown, Elkhart, Ind.), the signal of which went 
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through a matching transformer (MT-56R, Krohn-Hite, 
Avon, Mass.) to drive the transducer. 
Measurement of Ultrasound Pressure 
To monitor the ultrasound exposure, the voltage applied to 
the transducer was measured with an oscilloscope (54603B, 
Hewlett Packard, Santa Clara, Calif.). This voltage was used 
to estimate the incident ultrasound pressure, as described 
below. In addition, the signal from the hydrophone in the 
sample tube was fed to the oscilloscope and a spectrum 10 
analyzer (SR760, Stanford Research Systems), which was 
used to determine the amplitude of different acoustic signals 
shown in FIG. 2 and Table 1. Higher harmonics off (e.g., 
2f=48 kHz) are seen in FIG. 2, due to cavitation and 
apparatus resonance. Cavitation also generates other signals, 15 
including the subharmonic (f/2=12 kHz) and its ultrahar-
monics (e.g., 3f/2=36 kHz) and an elevated broadband 
"noise" level (e.g., bl, b2). The acoustic spectrum measured 
during exposure of cells to ultrasound provided information 
about cavitation and its effects on membrane permeability, 20 
as described below. 
25 
The strength of ultrasound is reported as its incident 
pressure. The incident pressure is defined as the pressure 
level that would exist in the absence of cavitation, which is 
primarily at the driving frequency (i.e., 24 kHz). The inci-
dent pressure is important because one of the effects of 
cavitation is to shift acoustic energy to frequencies other 
than the driving frequency, as shown in FIG. 2. Incident 
pressure is the most useful means to characterize ultrasound, 30 
because it is independent of apparatus geometry and repre-
sents the total relevant acoustic input. For propagating wave 
fields created by a planar transducer at high frequency, 
ultrasound strength is often reported as an intensity (e.g., in 
units W/cm2 ). For ultrasonic irradiation of a surface such as 35 
skin with a planar transducer, this approach seems appro-
priate (Kost and Langer, "Ultrasound-mediated transdermal 
drug delivery" in Topical Drug Bioavailability, Bioequiva-
lence, and Penetration (Shah & Maibach, eds.) pp. 91-104 
(Plenum Press, New York 1993)). In this experiment, how- 40 
ever, a radially-symmetric standing wave-like field is gen-
erated because of the cylindrical geometry of the transducer 
and because of the use of low frequency ultrasound with a 
wavelength comparable to the apparatus diameter, which 
field makes acoustic intensity extremely difficult to deter- 45 
mine. Alternatively, the reported pressure can be directly 
measured with a hydrophone at the driving frequency. While 
this approach is useful at low acoustic levels where the 
measured pressure has the same value as the incident 
pressure, at higher intensities where cavitation occurs, 50 
acoustic energy is shifted to a spectrum of other frequencies, 
10 
where peak positive pressure (P) has units of atmospheres 
and peak-to-peak voltage (V) has units of volts. This equa-
tion was extrapolated to higher voltages and pressures and 
was used to convert measured transducer voltages to the 
incident pressures described in these examples. 
Measurement of Ultrasound Power and Heating 
Bulk heating caused by ultrasound was measured and 
determined to be less than 1° C. for all exposures. Using an 
iron/constantant thermocouple (Model SAl-J thermocouple; 
Model DP 460 display; Omega Engineering, Stamford, 
Conn.) inserted into the water bath, which was mixed using 
a stir bar and magnetic stirrer (VWR), the temperature was 
determined to rise at 0.17° C./min. during continuous expo-
sure to ultrasound at 2.2 atm. and at 0.73° C./min. at 4.5 atm 
incident pressure. 
Although incident pressure, rather than power, is used to 
characterize the strength of ultrasound, it should be helpful 
to know the power of ultrasound exposures used here for 
comparison with other studies. Assuming that all acoustic 
energy from the transducer was eventually converted into 
heat and that heat loss from the apparatus to the surround-
ings was negligible, the measured heating rates described 
above can be used to determine the power output of the 
transducer with the equation 
(2) 
where W is power, mwater is the mass of water in the water 
bath (0.3 kg), CPwater is the heat capacity of water (4.18 J/g 0 
C.), and dT/dt is the change of temperature with respect to 
time (e.g., 0.17° C./min. at 2.2 atm.). For example, this 
equation yields 3.4 W at 2.2 atm and 15.1 W at 4.5 atm. 
using the heating rates given provided above. This type of 
calorimetric method is commonly used to estimate ultra-
sonic power (Kimura, et al., Ultrasonics Sonochem. 3: 
S157-S161 (1996)). 
A second method to determine the power of ultrasound 
exposures was to measure the electrical power supplied to 
the transducer. The values determined by the two methods 
should be equal if there is complete conversion of electrical 
power to acoustic power by the transducer (i.e., 100% 
efficiency). The voltage across the transducer was measured 
directly with an oscilloscope (model 2430A, Tektronics, 
Beaverton, Oreg.) and the current was measured using a 
current transformer (Model 2100, Pearson Electronics, Palo 
Alto, Calif.) and fed to the oscilloscope. The average power 
was calculated as the average of the product of the current 
and voltage signals and yielded the following relationship 
w~o.0001ov2 cr2~1.oo) (3) 
where power (W) has units of watts and peak-to-peak 
voltage (V) has units of volts. Combination of Equations 1 
and 3 yields the following equation which relates power to 
as shown in FIG. 2. Thus, the pressure measured at the 
driving frequency accounts for only a portion of the ultra-
sound exposure applied to the cells. 
The peak incident pressure generated within the exposure 
chamber was estimated by measuring the acoustic pressure 
55 
incident pressure for the experimental apparatus used herein: 
(4) 
where power (W) has units of watts and incident pressure (P) 
has units of atmospheres. This equation indicates the power 
is 6.3 W at 2.2 atm and 26 W at 4.5 atm, which are 
considerably higher than the values determined using Equa-
tion 2. This overprediction is expected, since Equation 4 
assumes 100% efficient conversion of electrical energy by 
the transducer into acoustic energy. In contrast, Equation 2 
at subcavitation levels and linearly extrapolating to higher 
drive levels (Matula, et al., J. Acoust. Soc. Am. 101: 1994-
2002 (1997)). At supra-cavitation levels, the incident pres-
sure continues to increase as a linear function of the voltage, 60 
whereas the measured pressure levels off and may decrease 
due to cavitation. A linear fit of the data was therefore 
generated only at low pressure (i.e., less than 2.0 atm. for 
degassed water) for the pressure as a function of transducer 
voltage: 65 yields an underprediction, since perfect insulation of the 
apparatus is assumed. Thus, Equations 2 and 4 provide upper 
and lower bounds for the acoustic energy. P~0.0089· V (r'~0.99) (1) 
US 7,273,458 B2 
11 
Post-Exposure Analysis 
After exposure to ultrasound, samples were removed from 
the sample tube and spun down, as described above. The 
supernatant contained free hemoglobin released from per-
meabilized cells, while the pellet contained intact cells. The 
supernatant was collected and the absorbance of hemoglobin 
in the supernatant was determined at 575 nm using a 
spectrophotometer (DU-64, Beckman Instruments). As a 
positive control, the absorbance was also determined for a 
sample in which all cells were lysed by suspension in 10 
deionized water. The ratio of these absorbances yielded the 
percent hemoglobin released, expressed as percent mem-
brane permeabilization in the Figures described herein. 
12 
driving frequency itself and its higher harmonics (set 1) 
showed the weakest correlation. Previous studies have cor-
related cell damage with Pf72 (Jeffers, et al., J. Acoust. Soc. 
Am. 97: 669-76 (1995)) and 20 f (Everbach, et al., Ultra-
sound Med. Biol. 23: 619-24 (1997)). Mechanistic interpre-
tation of these results is provided below. These correlations 
may provide a useful means for noninvasively measuring 
cell permeabilization by ultrasound. 
The effect of total exposure time of a single continuous 
ultrasound exposure is shown in FIG. 3. In each case, 
permeabilization increased with exposure time above a 
threshold of approximately 100 msec. Below approximately 
100 msec, ultrasound had little effect on the cells. For longer 
Results 15 exposures, membrane permeabilization increased as a strong 
function of exposure time. This is in qualitative agreement 
with previous studies conducted under somewhat different 
conditions, which also show that membrane disruption 
increases with exposure time above a threshold (Kober, et 
To develop a rational approach to designing protocols for 
ultrasound-mediated cell membrane permeabilization, the 
degree of permeabilization of bovine red blood cells 
exposed to low-frequency (24 kHz) ultrasound was mea-
sured as a function of incident ultrasound pressure, total 
exposure time, pulse length, and duty cycle. In addition, the 
amount of permeabilization was correlated with measurable 
acoustic signals, which is of interest to noninvasive moni-
toring of ultrasound's bioeffects and elucidation of mecha-
nisms. The degree of permeabilization was measured by 25 
release of hemoglobin from erythrocytes. 
20 al., J. Acoust. Soc. Am. 86: 6-7 (1989); Brayman, et al., 
Ultrasound Med. Biol. 22: 927-38 (1996)). 
FIG. la shows that permeabilization increased with 
increasing incident pressure (f=24 kHz), a measure of the 
total ultrasound exposure which cannot be measured directly 
in the presence of cavitation. Permeabilization exhibited an 30 
almost linear dependence for pressures greater than -0.5 
atm, which is consistent with previous studies which show 
that bioeffects increase with ultrasound pressure or intensity 
(Stewart & Stratmeyer, eds., An Overview of Ultrasound: 
In FIG. 4, cells were exposed to ultrasound using pulses 
of different length, but the cumulative "on" time for each set 
of pulses was kept constant at 10 sec by varying the total 
number of pulses. Pulses were applied at a duty cycle of 10% 
and at three different incident pressures: ( +) 0.89 atm., (•) 
2.7 atm., and C•) 8.9 atm. Permeabilization showed a weak 
dependence on pulse length, with a small, but statistically 
significant, peak at 3 msec. for both 2.7 atm. and 8.9 atm. 
(p<0.05, by Student's T-test, relative to average permeabi-
lization at pulse lengths~0.1 sec). For each pressure tested, 
the degree of membrane permeabilization varied little as a 
function of pulse length. There was, however, a small 
statistically-significant peak in permeabilization at 3 msec. A 
possible physical explanation for this peak is discussed 
below. 
For pulsed ultrasound, the effect of duty cycle (defined as 
the fraction of time that the ultrasound is "on" during pulsed 
application) is shown in FIG. 5. Under the conditions 
investigated, duty cycle had no significant effect on the 
degree of membrane permeabilization. 
FIG. lb shows that Pf72 is predictive of the degree of 
membrane permeabilization from exposures of different 
incident pressure, all having the same pulse length, exposure 
time, and duty cycle. To generalize the approach and con-
sider exposures of different pulse lengths, exposure times, 
duty cycles and incident pressures, membrane permeabili-
zation was correlated with the total exposure time (t), which 
Theory, Measurement, Medical Applications, and Biological 35 
Effects (FDA 82-8190), U.S. Department of Health and 
Human Services (Rockville, Md. 1983); Suslick, ed., Ultra-
sound: Its Chemical, Physical, and Biological Effects (VCH, 
Deerfield Beach, Fla. 1988); Barnett, et al., Ultrasound Med. 
Biol. 20: 205-18 (1994); Exposure Criteria for Medical 40 
Diagnostic Ultrasound: I. Criteria Based on Thermal 
Mechanisms (NCRP Report No. 113) (Bethesda, Md. 
1992)). FIG. lb shows that permeabilization increased with 
increasing subharmonic pressure (f/2=12 kHz), a measure of 
cavitation which can be measured directly. These figures 45 
indicate that membrane permeabilization is mediated by 
cavitation and that measurement of subharmonic pressure 
may be a noninvasive way to determine the degree of 
permeabilization (and thereby the amount of drug delivery) 
resulting from ultrasound exposure. 
FIG. 2 shows a representative spectrum of acoustic sig-
nals associated with an ultrasound exposure which causes 
extensive cavitation. A strong signal is seen at the driving 
frequency, f (i.e., 24 kHz), which is the frequency at which 
the transducer resonates. Due to cavitation and other effects, 55 
there are also strong signals at integer multiples of the 
driving frequency (e.g., 2f, 3f, and 4f) and at the subhar-
monic frequency, f/2, and its ultraharmonics (e.g., 3f/2, 5f/2, 
and 7f/2). The broadband noise pressure between these 
peaks (e.g., bl and b2) also is elevated. 
50 is equal to the product of pulse length and the number of 
pulses applied, multiplied by the strength of the f/2 signal 
(Pf72 ). As shown in FIG. 6, this parameter (i:·Pf72 ) correlated 
well with membrane permeabilization, showing a threshold 
value at approximately 0.01 (i.e., log (i:·Pf72 =-2). Below this 
threshold little permeabilization occurred, and above it per-
meabilization increased sharply. Because FIG. 6 includes all 
of the data collected in this study and because the parameter 
i:·Pf72 correlates well with the whole data set, it appears that 
measurement of this single parameter can provide a simple, 
60 non-invasive, and broadly-applicable method for determin-
ing membrane permeabilization caused by any acoustic It was assessed whether cell membrane permeabilization 
correlates with any of these features of the acoustic spec-
trum, as summarized in Table 1. The correlation was stron-
gest for Pf72 (i.e., the pressure at f/2) and its ultraharmonics 
(set 2). FIG. lb shows this relationship graphically. Perme- 65 
abilization also correlated with average measurements of 
broadband noise pressure between the peaks (set 3). The 
energy exposure. 
The parameter i:-Pf72 was chosen because it characterizes 
the total cavitational exposure by accounting for both the 
strength of the f/2 cavitation signal (Pf72 ) and the time over 
which it acts (i:). The good correlation between permeabi-
lization and i:-Pf72 is significant because measurement of this 
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single parameter can provide a simple, non-invasive method 
for determining membrane permeabilization caused by any 
ultrasound exposure. 
These studies showed that permeabilization increased 
with incident ultrasound pressure, increased with total expo-
sure time above a threshold of approximately 100 msec, 
showed a weak dependence on pulse length with a small 
maximum at 3 msec, and did not depend on duty cycle under 
the conditions examined. Using measured acoustic spectra, 
it was found that red blood cell membrane permeabilization 10 
correlated best with the pressure measured at half the driving 
frequency (f/2=12 kHz) and its ultraharmonics, less strongly 
with the broadband noise pressure measured between peaks, 
and least strongly with pressure measured at the driving 
frequency and its higher harmonics. Permeabilization 15 
caused by ultrasound applied at any set of conditions tested 
in this study could be well predicted by the parameter i:·Pf72 , 
which characterizes the total cavitational exposure. 
14 
signals which are known to be associated with cavitation. A 
good correlation was found for the pressure measured at half 
the driving frequency (f/2=12 kHz) and its ultraharmonics 
(FIG. lb, set 2 of Table 1). In addition, permeabilization 
caused by ultrasound applied at any set of conditions tested 
in this study could be well predicted by the parameteri:·Pf72 , 
which characterizes the total cavitational exposure by 
accounting for both the strength of the f/2 cavitation signal 
and the time over which it acts. 
Correlation of acoustic signals with membrane permeabi-
lization also provides mechanistic insight. The best corre-
lation was found for the signal at f/2 and its ultraharmonics 
(set 2 of Table 1, FIG. lb). This suggests that permeabili-
zation was mediated by cavitation. Onset of the f/2 signals 
is thought to occur with the onset of cavitation (Leighton, 
The Acoustic Bubble (1994)). As the cavitation activity 
increases, the f/2 signals also generally increase, but a 
quantitative relationship between amount of cavitation and Discussion 
Effect of Ultrasound Parameters 20 Pfl2 has not been established. Cavitation bubbles are thought 
to give off a signal at f/2 because of a prolonged expansion 
phase and delayed collapse which can occur during cavita-
tion (Leighton, The Acoustic Bubble (1994)). Measurement 
off/2 signals at the exact frequency of interest (e.g., 12 kHz; 
This study shows that permeabilization increases as a 
strong function of incident pressure (FIG. 1) and total 
exposure time (FIG. 3), which indicates that selection of 
appropriate pressure and duration of ultrasound exposure is 
important to achieve permeabilization at a desired level. The 
existence of a threshold near 100 msec of total exposure time 
(FIG. 3) also constrains possible protocols. In contrast, the 
observation that permeabilization depends only weakly on 
pulse length (FIG. 4) and duty cycle (FIG. 5) is useful, since 30 
it permits greater flexibility in designing ultrasound proto-
cols. 
25 set 2a) yielded a somewhat better correlation with perme-
abilization than measurement of the signal over the width of 
the peak (e.g., 11-13 kHz; set 2b). 
A reasonable correlation also was established for mea-
surements of broadband signals, or the signals between f, 
f/2, and higher harmonics (set 3 of Table 1), which also 
supports a permeabilization mechanism involving cavita-
tion, especially transient cavitation. Upon bubble collapse 
during transient cavitation, "noise" over a broad spectrum of 
35 frequencies is given off, which raises peak and broadband 
signals alike (Leighton, The Acoustic Bubble (1994)). Since 
both f/2 and broadband signals showed correlation, it 
appears that both stable and transient cavitation play a role 
The effects of different ultrasound parameters summa-
rized above can be explained in terms of cavitation, the 
mechanism by which membranes are believed to be dis-
rupted (Barnett, et al., Ultrasound Med. Biol. 20: 205-18 
(1994); Leighton, The Acoustic Bubble (Academic Press, 
London 1994)). It is well established that at greater acoustic 
pressure more cavitation bubbles with greater energy are 
created (Leighton, The Acoustic Bubble (1994)). Similarly, 40 
longer total exposure times also yield more cavitation 
bubbles. This increased cavitation should result in more 
extensive membrane permeabilization, as seen in FIGS. 1 
and 3. The minimum exposure time of 100 msec shown in 
FIG. 3 could result from the "warm-up" time it takes for 
bubbles to nucleate, grow, and possibly collapse over many 
ultrasound cycles (Margulis, Sov. Phys. Acoust. 22: 145-47 
(1976)). 
in membrane permeabilization. 
Finally, signals at f and its higher harmonics showed the 
poorest correlation (set 1 in Table 1). This was expected 
since these signals are related to the non-cavitational driving 
frequency (f) and resonance of the experimental apparatus 
45 (higher harmonics), in addition to stable and transient cavi-
tation. The signal f and its higher harmonics are not expected 
to be good indicators, since it reflects a mixture of effects. 
Conclusion 
This study provides a quantitative guide to designing 
ultrasound protocols useful for drug delivery. The acoustic 
measurements support the hypothesis that ultrasonic cavi-
tation is the mechanism by which membranes are perme-
abilized. They also indicate that measurable acoustic signals 
can provide noninvasive real-time feedback about mem-
brane permeabilization and drug delivery. 
Using red blood cells as a model system, it was shown that 
membrane permeabilization increases with incident ultra-
sound pressure, increases with total exposure time above a 
The maximum permeabilization observed for 3 msec 
pulses in FIG. 4 could be explained by two competing 50 
effects involving a mechanism proposed previously (Ciar-
avino, et al., Ultrasound Med. Biol. 7: 159-66 (1981)). 
Increasing pulse length is advantageous for cavitation 
because there is more time during each pulse for bubbles to 
nucleate, grow and collapse. However, it is believed that as 55 
pulse length increases so does the time between pulses at 
constant duty cycle, which means that as the interpulse delay 
increases, bubbles formed during the previous pulse have 
time to dissolve back into solution. This mechanism is 
disadvantageous because it leaves fewer nucleation bubbles 
available to grow and collapse during the next pulse, which 
results in less cavitation. 
60 threshold of 100 msec, shows a weak dependence on pulse 
length with a small maximum at 3 msec, and does not 
depend on duty cycle under the conditions examined. In 
addition, the degree of permeabilization was shown to Correlation with Measured Acoustic Signals 
Ultrasound causes cavitation which in turn causes effects 
on cells. Therefore the most useful predictor of ultrasound's 65 
effects on cells should be a measure of cavitation. Membrane 
permeabilization was correlated with measured acoustic 
correlate with measurable acoustic signals (e.g., Pf72 , i:·Pf72), 
which supports the belief that permeabilization is mediated 
by cavitation and may provide a method for noninvasive, 
real-time feedback for an intelligent delivery system. 
US 7,273,458 B2 
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TABLE 1 
Empirical Correlation of Membrane Permeabilization 
with Measured Acoustic Signals 
Frequency (kHz)" Correlated Equationb y2c 
Set la 24 (f)d M ~ 19.7 ln (P) + 30.6 0.58 
48 (2f) M ~ 12.4 ln (P) + 43.2 0.66 
72 (3f) M ~ 11.8 ln (P) + 49.2 0.58 
96 (4f) M ~ 11.4 ln (P) + 53.6 0.45 
Set lb 23-25 (f) M ~ 19.7 ln (P) + 65.0 0.64 
47-49 (2f) M ~ 12.7 ln (P) + 64.8 0.70 
71-73 (3f) M ~ 12.3 ln (P) + 68.9 0.66 
95-97 (4f) M ~ 11.7 ln (P) + 69.4 0.60 
Set 2a 12 (f/2) M ~ 9.4 ln (P) + 73.0 0.84 
36 (3f/2) M ~ 8.5 ln (P) + 64.7 0.85 
60 (5f/2) M ~ 8.7 ln (P) + 64.4 0.85 
84 (7f/2) M ~ 9.6 ln (P) + 69.6 0.85 
Set 2b 11-13 (f/2) M ~ 10.1 ln (P) + 79.8 0.81 
35-37 (3f/2) M ~ 9.0 ln (P) + 70.8 0.81 
59-61 (5f/2) M ~ 9.3 ln (P) + 70.3 0.82 
83-85 (7f/2) M ~ 9.8 ln (P) + 73.1 0.82 
Set 3 13-23 (bl) M ~ 10.2 ln (P) + 82.3 0.75 
25-35 (b2) M ~ 10.5 ln (P) + 82.9 0.75 
37-47 (b3) M ~ 10.2 ln (P) + 80.6 0.79 
49-59 (b4) M ~ 10.6 ln (P) + 78.2 0.78 
61-71 (b5) M ~ 10.3 ln (P) + 78.2 0.79 
73-83 (b6) M ~ 10.6 ln (P) + 79.7 0.79 
85-95 (b7) M ~ 10.2 ln (P) + 77.0 0.78 
aBased on spectral information such as that shown in FIG. 2, membrane 
permeabilization was correlated with the pressure (or the average pressure 
when a range of frequencies is given) measured at the frequency (or range 
of frequencies) indicated. 
bThe equation which resulted from a log-linear fit of membrane permeabi-
lization (M) and measured pressure (P) is shown. There is no mechanistic 
basis for the log-linear functionality; visual inspection suggested it was the 
most appropriate fit of the data. The units of permeabilization are percent 
hemog!obin released and the Wlits of pressure are atrn. 
cThe r correlation coefficient is shown for each fit of the data. 
dThe text in parentheses refers to which harmonic of the driving frequency 
(f ~ 24 kHz) the indicated frequencies correspond and "b" indicates a 
broadband noise measurement. 
EXAMPLE 2 
Ultrasound-Mediated Disruption of Prostate Tumor 
Cell Membranes 
Introduction 
The effects of ultrasound exposure on size, lifetime, and 
permeability of membrane disruptions in living cells were 
investigated quantitatively. It was found that ultrasound 
disruptions were a few nanometers in size, have a lifetime of 
approximately one minute, and induce extensive molecular 
uptake. 
Methods 
Prostate tumor cells (DU-145) were suspended in RPMI-
1640 medium with 10% fetal bovine serum at 5xl05 cells/ 
ml. For each experimental condition, a 3 ml polypropylene 
tube was filled with the cell suspension at room temperature 
(22±2° C.) and the top of the tube was closed without 
entrapping any air bubbles. The cells were exposed to 
ultrasound at 24 kHz in a chamber that consisted of a 
cylindrical piezoelectric transducer sandwiched between 
two PVC pipes and filled with deionized and degassed water 
at room temperature. Pressure, pulse length, duty cycle, and 
the total exposure time of ultrasound exposure were con-
trolled. Acoustic spectra during exposure were collected 
using a hydrophone placed in the exposure chamber. Cal-
cein, a green-fluorescent membrane-impermeant marker, 
dissolved in saline, was added to the suspensions either 
16 
before or at various times after exposure at a final concen-
tration of 10 µM. Other fluorescent markers, with different 
sizes, were also used to determine membrane permeability. 
The cells were kept at room temperature for 15 minutes after 
exposure, and then placed on ice until they were centrifuged 
and resuspended in phosphate-buffered saline with 0.1 
mg/ml of propidium iodide (a red-fluorescence viability 
stain). Cell-by-cell fluorescence was measured using flow 
cytometry, and 6 µm green-fluorescence microspheres were 
10 added to each sample at a constant concentration to provide 
an internal volumetric standard for determining concentra-
tions of viable cells. 
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Results and Discussion 
To better understand how cells are permeabilized by 
ultrasound, potential mechanisms of membrane disruptions 
were tested. First, it was observed that cells were perme-
abilized only in presence of extensive cavitation, as indi-
cated by characteristic changes in measured acoustic spectra 
20 (i.e., strong subharmonic and ultraharmonic peaks and broad 
band noise). Other effects of ultrasound, such as bulk heating 
and mixing were ruled out as potential mechanisms, since 
control experiments of heating (up to 2° C., the maximum 
temperature rise in these experiments) and mixing had 
25 negligible effects on cells. Also, cavitation-induced free 
radicals probably are not responsible, because membrane 
permeabilization was observed in the presence of free radi-
cal scavengers (e.g., 50 µM cysteamine). Therefore, micros-
cale hydrodynamic effects of cavitation probably are the 
30 main factor in disrupting cell membranes. 
The effects of ultrasound exposure parameters on cell 
viability and membrane permeabilization (as measured by 
uptake of calcein added to the cell suspension before expo-
sure) were determined to identify conditions that selectively 
35 permeabilize cells without killing them. As peak incident 
pressure increased, average cellular calcein uptake increased 
above a threshold and reached a plateau at 20-25% of 
external calcein concentration (FIG. 7). However, the frac-
tion of viable cells (relative to an unexposed suspension) 
40 decreased continuously with increasing pressure (FIG. 7). 
Uptake increased with total exposure time and reached a 
plateau at 5 sec. (for P=5.3 atm. and 10 ms pulses at 10% 
duty cycle), while cell viability decreased continuously. 
Average uptake showed a small maximum at 10-33 ms and 
45 a sharp decline at less than 3 ms, with changes in pulse 
length from 0.3 ms to 1.0 s. Applied duty cycle (from 0.5% 
to 80%) did not significantly affect uptake. Fraction of viable 
cells decreased as uptake increased for most conditions, and 
was approximately 25% for maximum uptake under optimal 
50 conditions. 
Membrane disruptions were found to be large enough to 
allow uptake of bovine serum albumen (radius, r approxi-
mately 3.5 nm). Average uptake of BSA molecules per 
exposed cell was about 60% less than that of calcein (r,.,0.7 
55 nm), for the same external concentration (10 µM) and same 
exposure conditions as given in FIG. 7 (at P=8.0 atm.). 
To determine lifetimes of the membrane disruptions, 
calcein was added to cell suspensions at different times after 
ultrasound exposure. As shown in FIG. 8, average uptake of 
60 calcein decreased exponentially with time at which calcein 
was added to a sample (~ 15 s after exposure). The data at 
three incident pressures, 5.3 atm. (o), 7.1 atm. (•),and 8.0 
atm. (-"), were fitted with exponential functions, and shown 
in FIG. 8. The respective time decay constants, i:, at these 
65 pressures were 78 sec., 66 sec, and 56 sec., respectively. One 
can see that the time decay constant, i:, decreased and the 
initial uptake increased with increasing incident pressure. 
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Average uptake was about 50% less when calcein was added 
15 sec. after exposure compared to when it was added before 
exposure for the examined pressures. However, significant 
uptake occurred for up to two minutes after exposure. 
Modifications and variations of the present invention will 
be obvious to those of skill in the art from the foregoing 
detailed description. Such modifications and variations are 
intended to come within the scope of the following claims. 
We claim: 
1. A method for altering cell viability or transport of 10 
chemical or biological agents into or through an internal 
organ, internal tissue or vessel in a human or other animal 
using acoustic energy, comprising: 
18 
administering acoustic energy at one or more frequencies 
by applying a transducer to a first site on the human or 
other animal other than where transport or cell viability 
is to be altered; 
wherein the acoustic energy is effective to alter transport 
or cell viability at a second site distant from the first site 
at a different tissue or an internal organ or an internal 
vessel in a different tissue, wherein the transducer is 
placed within a blood vessel using a catheter. 
3. A method for altering cell viability or transport of 
chemical or biological agents into or through an internal 
organ, internal tissue or vessel in a human or other animal 
administering acoustic energy at one or more frequencies 
by applying a transducer to a first site on the human or 
other animal other than where transport or cell viability 
is to be altered; 
15 using acoustic energy, comprising: 
wherein the acoustic energy is effective to alter transport 
or cell viability at a second site distant from the first site 
at a different tissue or an internal organ or an internal 20 
vessel in a different tissue, wherein the transducer is 
placed inside the body using invasive or minimally 
mvas1ve means. 
2. A method for altering cell viability or transport of 
chemical or biological agents into or through an internal 25 
organ, internal tissue or vessel in a human or other animal 
using acoustic energy, comprising: 
administering acoustic energy at one or more frequencies 
by applying a transducer to a first site on the human or 
other animal other than where transport or cell viability 
is to be altered; 
wherein the acoustic energy is effective to alter transport 
or cell viability at a second site distant from the first site 
at a different tissue or an internal organ or an internal 
vessel in a different tissue, wherein the transducer is 
placed within a surgical incision. 
* * * * * 
